Arsenic methylation capability, myeloperoxidase and sulfotransferase genetic polymorphisms, and the stage and grade of urothelial carcinoma

Urologia Internationalis

Volumn 82, Issue 2, 2009, Pages 227-234

  Huang, Steven K ^a,b   Chiu, Allen Wen Hsiang ^a,c   Pu, Yeong Shiau ^d   Huang, Yung Kai ^b   Chung, Chi Jung ^e   Tsai, Hui Ju ^f   Yang, Mo Hsiung ⁱ   Chen, Chien Jen ^g,h   Hsueh, Yu Mei ^f  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e Institute of Public Health   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g GENOMICS RESEARCH CENTER   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Arsenic exposure; Arsenic methylation; Bladder cancer; Myeloperoxidase; Sulfotransferase; Urinary arsenic species

Indexed keywords

ARSENIC; CACODYLIC ACID; DRINKING WATER; METHANEARSONIC ACID; MYELOPEROXIDASE; SULFOTRANSFERASE;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TIME SERIES ANALYSIS; URINALYSIS; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ARSENICALS; ARYLSULFOTRANSFERASE; CACODYLIC ACID; CARCINOMA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; METHYLATION; MIDDLE AGED; NEOPLASM STAGING; PEROXIDASE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SPECTROPHOTOMETRY, ATOMIC; URINARY BLADDER NEOPLASMS; UROTHELIUM; YOUNG ADULT;

EID: 63449122930     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200805     Document Type: Article

References (41)

1. Department of Health ROC: Cancer Registry Annual Report Republic of China, 1999 (in Chinese). Taipei, Department of Health, 2002.
2. Nseyo UO, Lamm DL: Therapy of superficial bladder cancer. Semin Oncol 1996; 23: 598-604.
3. Chen CJ, Chuang YC, Lin TM, Wu HY: Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985; 45: 5895-5899.
4. Serretta V, Morgia G, Altieri V, Pavone-Macaluso M, Scuto F, Allegro R, Di LA, Cindolo L, Melloni D: Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation. Urol Int 2006; 77: 152-158.
5. Lu CM, Chung MC, Huang CH, Ko YC: Interaction effect in bladder cancer between Nacetyltransferase 2 genotype and alcohol drinking. Urol Int 2005; 75: 360-364.
6. Andreae MO: Determination of arsenic species in natural waters. Anal Chem 1977; 49: 820-823.
7. Vahter M, Marafante E, Dencker L: Tissue distribution and retention of 74As-dimethylarsinic acid in mice and rats. Arch Environ Contam Toxicol 1984; 13: 259-264.
8. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ: Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 589-596.
9. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC: Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 2003; 14:303-310.
10. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, Yang MH, Chen CJ, Hsueh YM: Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 2007; 218: 99-106.
11. Kitchin KT, Ahmad S: Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol Lett 2003; 137: 3-13.
12. Hofstra AH, Uetrecht JP: Myeloperoxidasemediated activation of xenobiotics by human leukocytes. Toxicology 1993; 82: 221-242.
13. Petruska JM, Mosebrook DR, Jakab GJ, Trush MA: Myeloperoxidase-enhanced formation of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene-DNA adducts in lung tissue in vitro: a role of pulmonary inflammation in the bioactivation of a procarcinogen. Carcinogenesis 1992; 13: 1075-1081.
14. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, Loddenkemper R, Roots I: Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-649.
15. Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RW, Maas LM, Borm PJ, Drent M, Jacobs JA: Myeloperoxidase (MPO) -463G ] A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 2004; 13: 828-833.
16. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto di Carlo A, Porru S: GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 2004; 110: 598-604.
17. Glatt H, Meinl W: Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 55-68.
18. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Osada Y, Katoh T: Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 2004; 130: 99-106.
19. Wu MT, Wang YT, Ho CK, Wu DC, Lee YC, Hsu HK, Kao EL, Lee JM: SULT1A1 polymorphism and esophageal cancer in males. Int J Cancer 2003; 103: 101-104.
20. Pashos CL, Botteman MF, Laskin BL, Redaelli A: Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002; 10: 311-322.
21. World Health Organization: Histological Typing of Urinary Bladder Tumours; International Classification of Tumours. Geneva, World Health Organization, 1999.
22. Chen YC, Amarasiriwardena CJ, Hsueh YM, Christiani DC: Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol Biomarkers Prev 2002; 11:1427-1433.
23. Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, Lue LC, Chen CJ: Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 1998; 54: 431-444.
24. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM: Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 2005; 206: 299-308.
25. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR: Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 89-94.
26. Moore LE, Smith AH, Eng C, Kalman D, DeVries S, Bhargava V, Chew K, Moore D, Ferreccio C, Rey OA, Waldman FM: Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 2002; 94: 1688-1696.
27. Kitchin KT: Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001; 172: 249-261.
28. Gebel TW: Arsenic methylation is a process of detoxification through accelerated excretion. Int J Hyg Environ Health 2002; 205: 505-508.
29. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ: Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000; 74: 289-299.
30. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD: Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 2001; 14: 355-361.
31. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, Thomas DJ: Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 2001; 14: 305-311.
32. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, Mazumder DN, Hernandez AL, Smith AH: Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 2002; 110: 729-733.
33. Georgiou I, Filiadis IF, Alamanos Y, Bouba I, Giannakopoulos X, Lolis D: Glutathione Stransferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 2000; 37: 660-664.
34. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun WJ, Kim WJ: Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005; 65: 70-75.
35. Pi J, Qu W, Reece JM, Kumagai Y, Waalkes MP: Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res 2003; 290: 234-245.
36. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S: Point: myeloperoxidase -463G ] A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1550-1554.
37. Ahsan H, Chen Y, Kibriya MG, Islam MN, Slavkovich VN, Graziano JH, Santella RM: Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett 2003; 201: 57-65.
38. Kogevinas M, Trichopoulos D: Urinary bladder cancer; in Adami HO, Hunter D, Trichopoulos D (eds): Textbook of Cancer Epidemiology. New York, Oxford University Press, 2002, pp 446-466.
39. Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN, Meinl W: Sulfotransferases: genetics and role in toxicology. Toxicol Lett 2000; 112-113: 341-348.
40. Ozawa S, Katoh T, Inatomi H, Imai H, Kuroda Y, Ichiba M, Ohno Y: Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer 2002; 102: 418-421.
41. Yasuda S, Idell S, Fu J, Carter G, Snow R, Liu MC: Cigarette smoke toxicants as substrates and inhibitors for human cytosolic SULTs. Toxicol Appl Pharmacol 2007; 221: 13-20.